异体供者来源第二代CD19 CAR-T细胞治疗儿童复发/难治性B细胞前体急性淋巴细胞白血病
在豁免设置下测试供者来源第二代(4.1BB)CD19 CAR-T细胞治疗儿童复发/难治性B细胞前体急性淋巴细胞白血病。2021年3月至2022年10月共13例儿童/年轻成人接受输注,剂量1.0×10^6至3.0×10^6 CAR-T细胞/kg,毒性谱与自体CAR-T相当,全部获完全缓解且骨髓无微小残留病,中位随访12个月(范围5-21)时8/13维持完全缓解。
要点
- 13例复发/难治性B细胞前体急性淋巴细胞白血病患儿接受供者来源CD19 CAR-T细胞,全部达完全缓解且骨髓无微小残留病。
- 毒性以血细胞减少、细胞因子释放综合征(最高1级)和2级免疫效应细胞相关神经毒性综合征为主。
- 发生1例急性移植物抗宿主病,经类固醇和芦可替尼迅速控制;其余患者包括3例HLA单倍体供者均未发生移植物抗宿主病。
核心结论
- 异体抗CD19 CAR-T细胞可有效治疗异基因造血干细胞移植后复发的高度难治性B细胞前体急性淋巴细胞白血病,且与自体CAR-T细胞相比未显示毒性增加。
研究设计与样本
- 在医院豁免设置下测试供者来源T细胞经第二代(4.1BB)CD19 CAR转导的治疗,先后测试两种构建体:逆转录病毒构建体含自杀基因诱导型caspase-9(CD19-CAR-Retro_ALLO),随后为慢病毒构建体及基于Prodigy的自动化生产流程(CD19-CAR-Lenti_ALLO)。
- 2021年3月至2022年10月共13例儿童/年轻成人接受ALLO-CAR-T细胞输注。
- 输注剂量范围为1.0×10^6至3.0×10^6 CAR-T细胞/kg。
主要发现
- 毒性谱与自体CAR-T细胞相当,主要表现为血细胞减少、细胞因子释放综合征(最高1级)和2级免疫效应细胞相关神经毒性综合征。
- 发生1例急性移植物抗宿主病,经类固醇和芦可替尼迅速控制;其余患者包括3例接受HLA单倍体供者ALLO-CAR-T细胞者均未发生移植物抗宿主病。
- 2例在造血干细胞移植前接受ALLO-CAR-T细胞,显示CAR-T细胞显著扩增且无任何移植物抗宿主病征象。
- 全部患者获得完全缓解且骨髓无微小残留病。
- 中位随访12个月(范围5-21),13例中8例维持完全缓解。
临床怎么用
- 作者认为,异体抗CD19 CAR-T细胞可有效治疗异基因造血干细胞移植后复发的高度难治性B细胞前体急性淋巴细胞白血病,且与自体CAR-T细胞相比未显示毒性增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autologous CD19-directed chimeric antigen receptor (CAR)-T cells have shown unprecedented efficacy in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, patients either relapsing after allogeneic hematopoietic stem cell transplantation (allo-HSCT) or displaying profound lymphopenia and/or rapidly progressing disease often cannot access autologous products. These hurdles may be overcome by allogeneic, donor-derived CAR-T cells. We tested donor-derived T cells transduced with a second-generation (4.1BB) CD19-directed CAR for treatment of patients with BCP-ALL in a hospital-exemption setting. Two constructs were tested: a retroviral construct incorporating the suicide gene inducible caspase-9 (CD19-CAR-Retro_ALLO) first and then a lentiviral construct and an automated, Prodigy-based manufacturing process (CD19-CAR-Lenti_ALLO). Thirteen children/young adults received ALLO-CAR-T cells between March 2021 and October 2022. Doses ranged between 1.0 × 106 and 3.0 × 106 CAR-T cells per kg. The toxicity profile was comparable with that of autologous CAR-T cells, characterized mainly by cytopenia, cytokine release syndrome (maximum grade 1), and grade 2 immune-effector cell-associated neurotoxicity syndrome. One case of acute graft-versus-host disease (GVHD) occurred and was rapidly controlled with steroids and ruxolitinib. None of the other patients, including 3 given ALLO-CAR-T cells from an HLA-haploidentical donor, experienced GVHD. Two patients received ALLO-CAR-T cells before HSCT and showed a significant expansion of CAR-T cells without any sign of GVHD. All patients obtained complete remission (CR) with absence of minimal residual disease in the bone marrow. With a median follow-up of 12 months (range, 5-21), 8 of 13 patients maintained CR. Allogeneic anti-CD19 CAR-T cells can effectively treat highly refractory BCP-ALL relapsing after allo-HSCT without showing increased toxicity as compared with autologous CAR-T cells.
引用
- Del Bufalo F, Becilli M, Rosignoli C, et al. Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL. Blood. 2023. PMID: 37172203. doi:10.1182/blood.2023020023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。